In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery

Journal of Pharmaceutical Sciences

Volumn 102, Issue 1, 2013, Pages 126-135

  Zou, Aifeng ^a,b   Chen, Yan ^c   Huo, Meirong ^a   Wang, Jing ^a   Zhang, Yong ^a   Zhou, Jianping ^a   Zhang, Qiang ^d  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Yangtze River Pharmacy Group   (China)

^c Jiangsu Province Academy of Traditional Chinese Medicine   (China)

^d PEKING UNIVERSITY   (China)

Author keywords

Biomaterials; Cancer chemotherapy; Chitosan; Drug targeting; Polymeric drug delivery system

Indexed keywords

CHITOSAN; CYANINE DYE; DOXORUBICIN; MACROGOL; N CARBOXYMETHYLDIPEPTIDE; N OCTYL O, N CARBOXYMETHYL CHITOSAN; OCTREOTIDE; STEARIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STRUCTURE; DRUG TARGETING; IN VIVO STUDY; MICELLE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; TUMOR VOLUME; TUMOR XENOGRAFT; ZETA POTENTIAL;

EID: 84870671168     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23341     Document Type: Article

References (56)

1. Liu Y, Sun J, Zhang P, He Z. 2011. Amphiphilic polysaccharide-hydrophobicized graft polymeric micelles for drug delivery nanosystems. Curr Med Chem 18(17):2638-2648.
2. Liu J, Li HX, Chen DQ, Jin XA, Zhao XL, Zhang C, Ping QN. 2011. In vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel. Drug Deliv 18(3):181-189.
3. Torchilin VP. 2010. Polymeric micelles for therapeutic applications in medicine. Broz P, Ed. London, UK: Royal Society of Chemistry, pp 261-299.
4. Savić R, Luo L, Eisenberg A, Maysinger D. 2003. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300(5619):615-618.
5. Fang J, Nakamura H, Maeda H. 2011. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev 63(3):136-151.
6. Hatakeyama H, Akita H, Harashima H. 2011. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma. Adv Drug Deliver Rev 63(3):152-160.
7. Maruyama K. 2011. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliver Rev 63(3):161-169.
8. Torchilin V. 2011. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliver Rev 63(3):131-135.
9. Maeda H. 2010. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem 21(5):797-802.
10. Sancey L, Barbier E, Hirsjarvi S, Dufort S, Benoit JP, Remy C, Coll JL. 2011. Enhanced permeability and retention (EPR) effect in tumors: Characterization by MRI and fluorescence imaging. Bulletin du Cancer 98:S67-S67.
11. Kedar U, Phutane P, Shidhaye S, Kadam V. 2010. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6(6):714-729.
12. Richter A, Olbrich C, Krause M, Kissel T. 2010. Solubilization of sagopilone, a poorly water-soluble anticancer drug, using polymeric micelles for parenteral delivery. Int J Pharm 389(1-2):244-253.
13. Hilgenbrink AR, Low PS. 2005. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci 94(10):2135-2146.
14. Cheng D, Cao N, Chen JF, Yu XS, Shuai XT. 2012. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials 33(4):1170-1179.
15. Kawakami S, Higuchi Y, Hashida M. 2008. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci 97(2):726-745.
16. Pisal DS, Kosloski MP, Balu-Iyer SV. 2010. Delivery of therapeutic proteins. J Pharm Sci 99(6):2557-2575.
17. Shahin M, Ahmed S, Kaur K, Lavasanifar A. 2011. Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel. Biomaterials 32(22):5123-5133.
18. Mai J, Song S, Rui M, Liu D, Ding Q, Peng J, Xu Y. 2009. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J Control Release 139(3):174-181.
19. Zakhari JS, Zorrilla EP, Zhou B, Mayorov AV, Janda KD. 2012. Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. Mol Pharmaceut 9(2):281-289.
20. Herbst RS, Shin DM. 2002. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 94(5):1593-1611.
21. Yogesh CP. 1999. Somatostatin and its receptor family. Front Neuroendocrinol 20(3):157-198.
22. Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plöckinger U, Strowski MZ. 2007. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: An in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 92(2):673-680.
23. Grant M, Kumar U. 2010. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Peptides 159(1-3):3-8.
24. Seebach D, Widmer H, Capone S, Ernst R, Bremi T, Kieltsch I, Togni A, Monna D, Langenegger D, Hoyer D. 2009. NMR-solution structures and affinities for the human somatostatin G-protein-coupled receptors hsst(1-5) of CF(3) derivatives of sandostatin (R) (octreotide). Helv Chim Acta 92(12):2577-2586.
25. Grant M, Collier B, Kumar U. 2004. Agonist-dependent dissociation of human somatostatin receptor 2 dimers. J Biol Chem 279(35):36179-36183.
26. Grant M, Patel RC, Kumar U. 2004. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 279(37):38636-38643.
27. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. 2000. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 288(5463):154-157.
28. Pfeiffer M, Koch T, Schröder H, Laugsch M, Höllt V, Schulz S. 2002. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277(22):19762-19772.
29. Breeman W, de Jong M, Kwekkeboom D, Valkema R, Bakker W, Kooij P, Visser T, Krenning E. 2001. Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28(9):1421-1429.
30. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. 2008. Somatostatin analogues in the control of neuroendocrine tumours: Efficacy and mechanisms. Endocr Relat Cancer 15(3):701-720.
31. Shen Y, Ren ML, Shi YH, Zhang YX, Cai YL. 2011. Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro. Exp Ther Med 2(6):1171-1176.
32. Gatto F, Barbieri F, Castelletti L, Arvigo M, Pattarozzi A, Annunziata F, Saveanu A, Minuto F, Castellan L, Zona G, Florio T, Ferone D. 2011. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: Characterization of somatostatin receptor expression and role of subtype 5. Pituitary 14(2):141-147.
33. Ertilav M, Hur E, Bozkurt D, Sipahi S, Timur O, Sarsik B, Akcicek F, Duman S. 2011. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model. Nephrology 16(6):552-557.
34. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, Salmon A, Glaser B, Chisin R, Mishani E, Gross DJ. 2011. (68)Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with (111)In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol 13(3):583-593.
35. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, Virgolini IJ. 2011. Functional imaging in phaeochromocytoma and neuroblastoma with (68)Ga-DOTA-Tyr(3)-octreotide positron emission tomography and (123)I-metaiodobenzylguanidine. Eur J Nucl Med 38(5):865-873.
36. Guidoccio F, Grosso M, Maccauro M, Orsini F, Perri M, Boni G, Banti E, Grassetto G, Rubello D, Mariani G, Volterrani D. 2011. Current role of (111)In-DTPA-octreotide scintigraphy in diagnosis of thymic masses. Tumori 97(2):191-195.
37. Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G. 2011. Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications. J Pept Sci 17(2):154-162.
38. Zhang J, Jin W, Wang X, Wang J, Zhang X, Zhang Q. 2010. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm 7(4):1159-1168.
39. Sun M, Wang Y, Shen J, Xiao Y, Su Z, Ping Q. 2010. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Nanotechnology 21(47):475101.
40. Moody TW, Fuselier J, Coy DH, Mantey S, Pradhan T, Nakagawa T, Jensen RT. 2005. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides 26(9):1560-1566.
41. Sun ML, Wei JM, Wang XW, Li L, Wang P, Li M, Yi CH. 2007. Paclitaxel-octreotide conjugates inhibit growth of human non-small cell lung cancer cells in vitro. Exp Oncol 29(3):186-191.
42. Keller G, Schally AV, Nagy A, Baker B, Halmos G, Engel JB. 2006. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. Int J Oncol 28(6):1507-1513.
43. Iwase Y, Maitani Y. 2011. Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma. Mol Pharm 8(2):330-337.
44. Su ZG, Niu JX, Xiao YY, Ping QN, Sun MJ, Huang AW, You WL, Sang XY, Yuan DF. 2011. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol Pharm 8(5):1641-1651.
45. Lee K, Baek M, Park J, Lee J, Kim J, Lee H, Choi H. 2011. Characterization of impurities in the octreotide containing polylactic-co-glycolic acid microspheres prepared by an ultrasonic spray drying process. Biopolymers 96(4):515-515.
46. Han GC, Ouyang Y, Long XY, Zhou Y, Li M, Liu YN, Kraatz HB. 2010. (Carboxymethyl-dextran)-modified magnetic nanoparticles conjugated to octreotide for MRI applications. Eur J Inorg Chem 2010(34):5455-5461.
47. Zhang Y, Zhang H, Wang X, Wang J, Zhang X, Zhang Q. 2012. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 33(2):679-691.
48. Zou A, Huo M, Yin X, Yao C, Zhu Q, Zhang M, Ren J. 2011. Octreotide-mediated N-octyl-O, N-carboxymethyl chitosan micelles:preparation, characterization and research as doxorubicin delivery vectors. J China Pharm Univ 42(2):124-130.
49. Zou A, Huo M, Zhang Y, Zhou J, Yin X, Yao C, Zhu Q, Zhang M, Ren J, Zhang Q. 2012. Octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles as potential carriers for targeted antitumor drug delivery. J Pharm Sci 101(2):627-640.
50. Petrangolini G, Supino R, Pratesi G, Bo LD, Tortoreto M, Croce AC, Misiano P, Belfiore P, Farina C, Zunino F. 2006. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther 318(3):939-946.
51. Rawat MK, Jain A, Singh S. 2011. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: In vitro and in vivo evaluation. J Pharm Sci 100(6):2366-2378.
52. Pan J, Feng SS. 2008. Targeted delivery of paclitaxel using folate-decorated poly(lactide) - vitamin E TPGS nanoparticles. Biomaterials 29(17):2663-2672.
53. Gill KK, Nazzal S, Kaddoumi A. 2011. Paclitaxel loaded PEG5000-DSPE micelles as pulmonary delivery platform: Formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 79(2):276-284.
54. Hengerer A, Wunder A, Wagenaar DJ, Vija AH, Shah M, Grimm J. 2005. From genomics to clinical molecular imaging. Proceedings of the IEEE 93(4):819-828.
55. Kim T-H, Mount CW, Gombotz WR, Pun SH. 2010. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials 31(28):7386-7397.
56. Daruwalla J, Nikfarjam M, Greish K, Malcontenti-Wilson C, Muralidharan V, Christophi C, Maeda H. 2010. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: Survival improvement and inhibition of liver metastases. Cancer Sci 101(8):1866-1874.